Skip to main content

Osimertinib and Chemotherapy Improves PFS in Advanced EGFRm NSCLC

*May 2023*

Positive findings from the FLAURA2 study add to the body of evidence supporting treatment with osimertinib for patients with EGFRm non–small cell lung cancer.mpared to osimertinib alone and as such, can further delay treatment resistance and disease progression.”

The combination of osimertinib (Tagrisso) with chemotherapy generated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs osimertinib alone for the treatment of patients with locally advanced or metastatic EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC), according to results from the phase 3 FLAURA2 trial (NCT04035486).1

In addition, the safety data and discontinuation rates due to adverse events observed with the combination were consistent with the established profiles of each agent alone. The overall survival (OS) data were immature at the time of this analysis and will be formally assessed at a subsequent analysis.

These findings add to the body of evidence supporting osimertinib for the treatment of patients with EGFRm NSCLC, as it has shown to improve outcomes in patients with early-stage disease in the phase 3 ADAURA trial (NCT02511106), as well as now in this trial for patients with late-stage disease. Read more.